Dr. Matthias Riedl, widely recognized as the “Ernährungs-Doc” in German-speaking media, has renewed his call for weight-loss medications to be covered by statutory health insurance in Germany, arguing that such treatments should be accessible to patients struggling with obesity-related health conditions.
The physician and nutrition specialist made the statement during a recent episode of his YouTube series, where he discussed the growing role of pharmacological interventions in managing chronic weight issues. His remarks approach amid increasing public and medical debate over the cost-effectiveness and accessibility of newer anti-obesity drugs, particularly glucagon-like peptide-1 (GLP-1) receptor agonists.
Riedl emphasized that obesity should be treated as a chronic medical condition rather than a lifestyle shortcoming and that evidence-based pharmacotherapy, when combined with nutritional counseling and lifestyle support, can significantly improve long-term health outcomes for patients.
He pointed to clinical data showing that medications like semaglutide and tirzepatide can lead to sustained weight reduction and improvements in comorbidities such as type 2 diabetes, hypertension, and dyslipidemia when used under medical supervision.
According to Riedl, restricting access to these treatments based on cost creates inequities in care, especially for individuals from lower socioeconomic backgrounds who may benefit most from intervention but lack the financial means to pay out-of-pocket.
The Ernährungs-Doc has previously advocated for a more individualized approach to nutrition and metabolic health, cautioning against overreliance on genetic testing for dietary planning while supporting the utilize of validated biomarkers and metabolic assessments to guide personalized care.
In his public communications, Riedl consistently stresses that no medication replaces the need for balanced nutrition and physical activity, but that pharmacological tools can serve as an important adjunct for patients who have not achieved sufficient results through lifestyle changes alone.
His latest remarks align with ongoing discussions within German healthcare policy circles about expanding the formulary of statutory health insurers to include certain weight-loss medications under specific clinical indications.
Currently, most GLP-1-based therapies for obesity are not routinely reimbursed by German public health insurers unless prescribed for diabetes management, leaving many patients to bear the full cost, which can exceed €100 per month depending on the formulation and dosage.
Riedl argued that early intervention with effective treatments could reduce long-term burdens on the healthcare system by preventing complications associated with severe obesity, such as cardiovascular events, joint degeneration, and fatty liver disease.
He called for clearer clinical guidelines from professional medical societies to define eligibility criteria for insurance coverage, including thresholds for body mass index (BMI), presence of comorbid conditions, and documented failure of prior non-pharmacological interventions.
The Ernährungs-Doc also highlighted the importance of medical supervision when using these drugs, noting that side effects such as gastrointestinal discomfort, nausea, and, in rare cases, pancreatitis or gallbladder issues require monitoring by qualified healthcare providers.
He dismissed concerns about overprescription, stating that responsible use under physician guidance minimizes risks, and that fears of misuse should not deny effective treatment to those who need it.
Riedl’s position reflects a broader shift in European medical thinking toward recognizing obesity as a complex, multifactorial disease influenced by genetic, environmental, and behavioral factors, rather than solely a matter of personal willpower.
His advocacy builds on years of public education through television appearances, podcasts, and social media, where he has consistently promoted science-based nutrition and cautioned against fad diets and unproven supplements.
The physician, who holds a medical degree and has worked in clinical practice and preventive medicine, frequently collaborates with other specialists to provide interdisciplinary care for patients with metabolic disorders.
While he supports innovation in treatment, Riedl remains cautious about emerging trends such as direct-to-consumer genetic tests for nutrition, which he has said lack sufficient scientific validation to justify routine use in clinical practice.
Instead, he recommends focusing on measurable health markers like blood glucose, lipid profiles, inflammation indicators, and body composition when tailoring dietary and therapeutic plans.
Regarding the cost of weight-loss medications, Riedl noted that prices may decrease over time as patents expire and biosimilars enter the market, but that waiting for affordability should not delay care for those currently suffering from obesity-related morbidity.
He urged policymakers to consider value-based pricing models and outcome-linked reimbursement schemes that tie coverage to measurable health improvements, ensuring that public funds are used effectively.
The Ernährungs-Doc concluded by calling for a compassionate, evidence-driven approach to obesity care that integrates medical, nutritional, and psychological support — one that treats patients with dignity and offers them real pathways to better health.
As of now, no official changes to German reimbursement policy for anti-obesity medications have been announced, but Riedl’s advocacy contributes to an ongoing conversation that may influence future decisions by the Federal Joint Committee (G-BA), which governs the benefits catalog of statutory health insurance in Germany.
Readers seeking updated information on coverage policies for weight-loss treatments in Germany are encouraged to consult the official website of the G-BA or speak with their healthcare provider about individual eligibility and available options.
If you found this overview informative, please consider sharing it with others who may benefit from understanding the evolving landscape of obesity treatment and healthcare access.